
Limitation of Infarct Size
Springer (Publisher)
1st Edition
Published on 16. December 1988
Book
Paperback/Softback
XVI, 279 pages
978-3-540-19148-3 (ISBN)
Description
Effective treatment of acute myocardial infarction remains one of the major issues in cardiology and internal medicine. The present monograph summarizes the relevant experimental data and the results of major clinical trials in the treatment of myocardial infarction. There are contributions of fundamental anatomical and physiological concepts of vascular occlusion and myocardial damage due to ischemia as well as discussions of therapeutic strategies involving thrombolytic agents, adjuvant drug therapy for limitation of myocardial damage, improvement in myocardial tolerance to ischemia and prevention of coronary reocclusion. In this regard, there is an extensive discussion of the role of coronary angioplasty and bypass surgery in the setting of acute myocardial infarction.
More details
Language
English
Place of publication
Berlin
Germany
Publishing group
Springer Berlin
Target group
Professional and scholarly
Research
Illustrations
22 s/w Abbildungen
XVI, 279 p. 22 illus.
Dimensions
Height: 244 mm
Width: 170 mm
Thickness: 17 mm
Weight
515 gr
ISBN-13
978-3-540-19148-3 (9783540191483)
DOI
10.1007/978-3-642-73585-1
Schweitzer Classification
Other editions
Additional editions

Horst Schmutzler | Wolfgang Rutsch | Frank C. Dougherty
Limitation of Infarct Size
E-Book
12/2012
Springer
€96.29
Available for download
Content
Pathogenesis and Pathophysiology of Coronary Occlusion.- Can Infarct Size Be Limited? Prospects for "Injury-Delaying" Therapy.- Pathophysiology of Evolving Myocardial Infarction.- The Pathogenesis of Thrombosis in Human Atherosclerotic Coronary Arteries.- Thrombogenesis and Vascular Occlusion.- Evaluation of Myocardial Perfusion by Means of Contrast Echocardiography.- Discussion (edited by R. Parratt).- Limitation of Infarct Size by Nonthrombolytic Drugs.- Estimation of Acute Infarct Size In Vivo.- Pharmacology of Cardioprotection.- Calcium Antagonists and Ischaemia: A Critical Evaluation.- Can Myocardial Infarction Be Prevented or Limited by Nonthrombolytic Drugs?.- Newer Aspects of Drug Therapy: Free Radical Scavengers.- Stimulation of Vascular Prostacyclin Formation by Defibrotide: A New Strategy for Treatment of Acute Myocardial Ischaemia.- Discussion (edited by P. Lichtlen).- Limitation of Infarct Size by Thrombolytic Therapy.- Thrombolytic Therapy: State of the Art.- Early and Prehospital Thrombolytic Therapy in Acute Myocardial Infarction.- Status of Thrombolytic Therapy in Acute Myocardial Infarction in France.- Adjuvant Therapy for Coronary Reperfusion in Evolving Acute Myocardial Infarction.- Perspectives on Newer Thrombolytic Agents.- Discussion (edited by F. C. Dougherty).- Follow-up Therapy after Thrombolysis.- Is Immediate Angioplasty Required to Restore Coronary Blood Flow at Rest After Recanalisation with Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction?.- Angioplasty After Thrombolysis: Early and Late Angiographic Results.- PTCA in Acute Myocardial Infarction.- What is the Place of Surgery Soon After Thrombolysis?.- The Use of Cardiovascular Drugs Following Thrombolysis in Humans.- Discussion(edited by F. C. Dougherty).- Prevention of Occlusion or Reocclusion.- Factors Influencing the Rate of Coronary Artery Occlusion and Reocclusion.- Which Antithrombotic Therapy Has Proven Most Effective for the Treatment of Deep Arterial Injury, Ruptured Plaque, and Post-Thrombolysis?.- Agents Effective in the Limitation of Myocardial Ischaemic Damage: Present Concepts and Future Possibilities.- Discussion (edited by F. C. Dougherty).- Therapeutic Strategies for Limitation of Infarct Size.- Panel members.